Skip to content

Increased Peri-implant Keratinized Mucosal Thickness at Different Operative Times

The Effect of Different Surgical Timing on the Clinical Efficacy of Increasing the Thickness of Keratinized Mucosa Around a Single Posterior Implant: a Prospective, Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04683991
Enrollment
34
Registered
2020-12-24
Start date
2021-05-27
Completion date
2023-12-31
Last updated
2022-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Implants, Peri-Implantitis

Keywords

keratinized mucosa thickness, dental Implants, subepithelial connective tissue graft, marginal bone level

Brief summary

Keratinized mucosa, which is composed of free gingiva and attached gingiva, is a barrier against bacterial invasion in oral cavity and provides good tissue sealing for periodontal environment. When the keratinized mucosa is insufficient, it is difficult to maintain the long-term stability of the implant, which is not conducive to the peri-implant health. It is generally believed that enough keratinized mucosa width is beneficial to reduce plaque accumulation and reduce the incidence rate of peri-implant diseases. In recent years, clinicians have gradually recognized that the thickness of keratinized mucosa plays an important role in maintaining the peri-implant health. Some researchers found that the thickness of mucosa is very important to maintain the aesthetic effect of implant restoration, and when the thickness of mucosa around the implant is less than 2mm, alveolar bone absorption will occur to maintain a stable biological width. A meta-analysis showed that when the thickness of the keratinized mucosa around the implant was greater than 2mm, the amount of marginal bone loss was significantly reduced (- 0.8mm, P \< 0.0001). It is considered that autogenous soft tissue graft is the most reliable technology to augment keratinized mucosa. Subepithelial connective tissue graft (SCTG) is a mucogingival surgery that transplant autologous free connective tissue under the pedicled semi thick flap to augment keratinized mucosa. It can effectively increase the thickness of soft tissue, cover the exposed implant, and reconstruct the interdental papilla. It is the gold standard for peri-implant soft tissue agumentation. Keratinized mucosal thickening surgery may be done prior to the surgical phase, after the surgical phase, before loading, or even after loading. It is believed that keratinized mucosal thickening at the same time of implantation can effectively reduce the possibility of mucosal recession after implantation, reduce the amount of marginal bone absorption in the process of osseointegration, which is conducive to maintaining the long-term stability of the implant. For the sake of clear clinical vision and convenient operation, clinicians often choose to thicken the keratinized mucosa during the secondary operation, and also obtain good postoperative effect. However, after the completion of the final repair, the keratinized mucosa thickening surgery increases the difficulty of operation and the technical requirements for the operator. In clinical practice, it is rarely selected to perform keratinized mucosal thickening at this time. At present, the effectiveness of timing on the outcome of soft tissue augmentation is still debated, and, most importantly, a direct comparison between simultaneous and staged procedures remains underexplored. Therefore, this clinical trial is to prospectively compare the clinical efficacy of simultaneous versus delayed timing of soft tissue augmentation by SCTG placement around single implants, by evaluating the peri-implant marginal bone level change and soft tissue change, so as to provide reference for the formulation of clinical treatment plan and the selection of the best operation time.

Interventions

A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS26.0 will be placed in sequentially coded, sealed, opaque envelopes. Only 1 or 0 will be generated, and the number of 1 or 0 generated by SPSS26.0 is 17. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The number 1 represented the treatment group 1 and the number 0 represented the treatment group 2.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* No systemic diseases or pregnancy; * The thickness of keratinized mucosa where the posterior tooth is missing is less than 2 mm; * Full-mouth plaque score (FMPS) \< 20% (measured at four sites per tooth) and bleeding on probing score (BOP%) ≤25% (measured at six sites per tooth); * Periodontal condition is stable, no probing depths ≥5 mm; * No previous soft tissue augmentation procedure at experimental site; * The patient has signed informed consent and accepts the operation of subepithelial connective tissue transplantation.

Exclusion criteria

* Patients with uncontrolled hypertension; * Patients with uncontrolled diabetes; * Patients with insufficient oral hygiene and Untreated periodontitis; * Pregnant or lactating women; * Smoker; * Patients with long-term (\> 6 months) use of glucocorticoids; * History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 5 years; * Patients with severe cardiovascular problems; * Patients with uncontrolled infectious or metabolic diseases; * Patients with substance abuse.

Design outcomes

Primary

MeasureTime frameDescription
peri-implant marginal bone level change18 monthsThe bone level of the proximal and distal sites of the implant is measured by oral X-ray parallel projection method. Compare the image value with the actual value to calculate the actual bone level.

Secondary

MeasureTime frameDescription
peri-implant keratinized mucosa width18 monthskeratinized tissue measured as the distance between muco-gingival junction and the gingival margin.
peri-implant keratinized mucosa thickness18 monthsgingival thickness measured 1.5 mm coronal to the MGJ using an injection needle, perpendicular to the tissue surface, with a silicon stop over the gingival surface.
peri-implant clinical attachment level change18 monthsThe distance between the reference point of impression edge and the bottom of gingival groove around the implant.
peri-implant gingival recession18 monthsThe distance between the implant shoulder and the gingival margin of the temporary or final crown was measured with a periodontal probe (only when the implant shoulder was visible).
visual analogue scale18 monthsVisual analogous scale ( VAS) suggested by WHO was used to assess. Analgesia intensity expressed with 0-10, 0 point as without pain completely, 10 points as unbearable pain.
peri-implant gingival index18 monthsPeriodontal probe was used to measure 6 sites on buccal and lingual side each time to observe gingival color, texture and bleeding, and record the scores.

Countries

China

Contacts

Primary ContactWeilian Sun, PhD
weiliansun@zju.edu.cn13757119563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026